tiprankstipranks
Advertisement
Advertisement

HK:0460 Stock Latest News

Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit
Company AnnouncementsSihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit
3d ago
Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges
PremiumCompany Announcements
Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges
8d ago
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
PremiumCompany Announcements
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
9d ago
Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma
PremiumCompany Announcements
Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma
30d ago
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
PremiumCompany Announcements
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
1M ago
Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
PremiumCompany AnnouncementsSihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
1M ago
Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation
Premium
Company Announcements
Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation
1M ago
Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori
Premium
Company Announcements
Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori
1M ago
Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion
PremiumCompany Announcements
Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion
1M ago
Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets
PremiumCompany Announcements
Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets
1M ago
Sihuan Pharma Teams With Biocytogen on AI-Driven Obesity Drug R&D
PremiumCompany Announcements
Sihuan Pharma Teams With Biocytogen on AI-Driven Obesity Drug R&D
2M ago
Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins
PremiumCompany Announcements
Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins
2M ago
Sihuan Pharmaceutical Declares Final Cash Dividend for 2025
PremiumCompany AnnouncementsSihuan Pharmaceutical Declares Final Cash Dividend for 2025
2M ago
Sihuan Pharma Subsidiary Xuanzhu Narrows Loss as Revenue Doubles in 2025
Premium
Company Announcements
Sihuan Pharma Subsidiary Xuanzhu Narrows Loss as Revenue Doubles in 2025
2M ago
Sihuan’s Bireociclib Delivers Strong Phase 3 Breast Cancer Data Published in JAMA Oncology
Premium
Company Announcements
Sihuan’s Bireociclib Delivers Strong Phase 3 Breast Cancer Data Published in JAMA Oncology
2M ago
Sihuan Unit Completes Phase III Enrollment for Novel Reflux Esophagitis Drug in China
PremiumCompany Announcements
Sihuan Unit Completes Phase III Enrollment for Novel Reflux Esophagitis Drug in China
2M ago
Sihuan Pharmaceutical Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
PremiumCompany Announcements
Sihuan Pharmaceutical Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
2M ago
Sihuan Pharma Subsidiary Xuanzhu Biopharm Added to Hong Kong Stock Connect
PremiumCompany Announcements
Sihuan Pharma Subsidiary Xuanzhu Biopharm Added to Hong Kong Stock Connect
2M ago
Sihuan’s Bireociclib Wins First-Line Breast Cancer Approval, Extending Lead in China
PremiumCompany Announcements
Sihuan’s Bireociclib Wins First-Line Breast Cancer Approval, Extending Lead in China
3M ago
Sihuan Subsidiary Xuanzhu Biopharm Joins Hang Seng Composite Index, Opening Path to Stock Connect
PremiumCompany AnnouncementsSihuan Subsidiary Xuanzhu Biopharm Joins Hang Seng Composite Index, Opening Path to Stock Connect
3M ago
Sihuan Pharmaceutical Forecasts Strong 2025 Profit on Booming Aesthetics and Drug Growth
Premium
Company Announcements
Sihuan Pharmaceutical Forecasts Strong 2025 Profit on Booming Aesthetics and Drug Growth
3M ago
Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications
Premium
Company Announcements
Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >